Leaders in Pharmaceutical Business Intelligence (LPBI) Group

In Eli Lilly’s Pipeline: DISCONTINUING Evacetrapib, a CETP inhibitor that’s meant to boost HDL

Reporter: Aviva Lev-Ari, PhD, RN

• Pharma giant Eli Lilly’s pipeline lost a star contender on Monday when the company disclosed that it would be discontinuing trials for evacetrapib, a lead CVD drug candidate that the Indianapolis-based pharma believed would eventually garner blockbuster sales.
• Lilly had poured millions into massive phase 3 trials for the drug and enrolled more than 12,000 people in safety and efficacy studies. But the independent committee overlooking the trials informed the company that “there was a low probability the study would achieve its primary endpoint based on results to date” and that the candidate demonstrated “insufficient efficacy.”
• Evacetrapib is a CETP inhibitor that’s meant to boost HDL (aka “good cholesterol”) in order to guard against heart attacks and strokes. Analysts had expected the drug to achieve anywhere from $1 billion to nearly $4 billion in sales if approved.

Other related articles on HDL published on this Open Access Online Scientific Journal include the following: 

http://pharmaceuticalintelligence.com/?s=HDL